Bernstein E P
Department of Obstetrics and Gynecology, Mount Sinai Hospital, Toronto, Canada.
J Reprod Med. 1993 Jan;38(1 Suppl):73-7.
A commercially prepared prostaglandin E2 (PGE2) gel for cervical ripening has been approved by the U.S. Food and Drug Administration (FDA). In circumstances when labor must be induced before the cervix has undergone spontaneous softening and effacement, this product effectively prepares the cervix for labor. Compared with extemporaneous preparations for vaginal administration, this product offers stability, uniform dosage and minimal side effects. Intracervical PGE2 gel offers significant clinical benefits, but also requires consideration of important clinical issues related to the selection of patients, application of the gel and subsequent monitoring of the patient and fetus.
一种用于宫颈成熟的市售前列腺素E2(PGE2)凝胶已获美国食品药品监督管理局(FDA)批准。在宫颈尚未自然软化和消退而必须引产的情况下,该产品能有效地使宫颈为分娩做好准备。与临时配制的阴道给药制剂相比,该产品具有稳定性、剂量均匀且副作用最小的优点。宫颈内使用PGE2凝胶有显著的临床益处,但也需要考虑与患者选择、凝胶应用以及随后对患者和胎儿的监测相关的重要临床问题。